Immunocore was recognized as SCRIP Awards 2015’s Biotech of the Year. Immunocore is a world-leading biotech company developing novel T cell receptor (TCR) based biological drugs for the treatment of cancer, viral infections and autoimmune disease.
Telesta Therapeutics announced that the company will not start another Phase III clinical trial on its own of MCNA, a drug for high-risk, non-muscle invasive bladder cancer patients.
The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
GSK’s Nucala® (mepolizumab) receives approval from US FDA Issued: London UK – LSE Announcement First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype GlaxoSmithKline plc […]
After months of speculation on who Pfizer Inc. (PFE) will attempt to buy are now officially over — sort of. It has been confirmed that Pfizer Inc. and Allergan Plc […]
U.S. health regulators on Tuesday approved Amgen Inc’s novel cancer immunotherapy for injection into melanoma lesions and lymph nodes of patients with the deadliest form of skin cancer that returns […]
RIDGEFIELD, Conn., Oct. 16, 2015 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) granted approval of Praxbind® (idarucizumab). PRAXBIND is indicated for patients treated […]
Thousand Oaks, Calif.-based Amgen (AMGN), faced with generic and biosimilars competition as its blockbusters lose patent protection, is fighting back on a number of fronts. On Oct. 2, 2015, […]
